Cargando…
Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study
Background: ICIs have dramatically improved patient outcomes in different malignancies. However, the impact of liver metastases (LM) and number of metastatic sites (MS) remains unclear in patients treated with single-agent anti-PD(L)1. Methods: We aimed to assess the prognostic impact of LM and MS n...
Autores principales: | Maugeais, Madeleine, Péron, Julien, Dalle, Stéphane, Boespflug, Amélie, Duruissaux, Michaël, Corbaux, Pauline, Reverdy, Thibault, Sahin, Gulsum, Rabier, Aurélie, Lopez, Jonathan, Freymond, Nathalie, Maillet, Denis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855949/ https://www.ncbi.nlm.nih.gov/pubmed/36672591 http://dx.doi.org/10.3390/biomedicines11010083 |
Ejemplares similares
-
Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes
por: de la Bruyère, Charline Lafayolle, et al.
Publicado: (2021) -
Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab
por: Pham, Félix, et al.
Publicado: (2022) -
HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
por: Essadi, Ismail, et al.
Publicado: (2023) -
Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date
por: Boespflug, Amélie, et al.
Publicado: (2017) -
Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma
por: Mangin, Marie‐Alix, et al.
Publicado: (2021)